TrialBritish journal of cancer2018

A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin.

Yi Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.